Physician
Comprehensive Neurology Center, PLLC
Comprehensive Neurology Center, PLLC was paid $2.84M by Medicaid between Jan 2018 and Dec 2024, across 25 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 56% of everything it billed.
33Billing provider infoCOMPREHENSIVE NEUROLOGY CENTER, PLLC
MURFREESBORO, TN 37128
MURFREESBORO, TN 37128
33aNPI1588944532assigned 08/23/2011
33bProvider typeNeurology Physician
28Total paid$2.84M
24GClaims150,022
24DCodes billed25
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Neurology Physician providers in Tennessee
Rank by total paid#4 of 83
Median peer was paid$27K
This provider vs. median107×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,046 | $216K | |
| 2019 | 24,176 | $485K | |
| 2020 | 22,944 | $450K | |
| 2021 | 24,663 | $404K | |
| 2022 | 24,428 | $476K | |
| 2023 | 23,250 | $424K | |
| 2024incomplete | 16,515 | $389K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 56% | 60,481 | 45,404 | $1.59M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 23,354 | 18,311 | $415K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 9.4% | 24,359 | 18,729 | $268K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 9.1% | 15,260 | 12,288 | $258K |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 7.0% | 6,715 | 5,176 | $200K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.8% | 1,042 | 795 | $52K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 914 | 832 | $26K |
| 64483 | <1% | 151 | 118 | $10K | |
| 64493 | <1% | 149 | 79 | $7K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 205 | 175 | $7K |
| 64494 | <1% | 105 | 53 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 481 | 352 | $3K |
13 more codes
| 20610 | <1% | 73 | $2K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 387 | $2K |
| 64635 | <1% | 14 | $2K | |
| 64636 | <1% | 14 | $650.93 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 628 | $308.23 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 443 | $250.01 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 18 | $43.58 |
| 99441 | <1% | 17 | $22.13 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 332 | $9.06 |
| G8428 | Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given | 0% | 221 | $0.00 |
| G8430 | Documentation of a medical reason(s) for not documenting, updating, or reviewing the patient's current medications list (e.g., patient is in an acute health crisis where time is of the essence and delay of treatment would jeopardize the patient's health status) | 0% | 29 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 11,405 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 3,225 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHNEIDER, JOHN (MD/PRESIDENT)